Neoadjuvant immunochemotherapy improves outcomes for gastric cancer patients

Neoadjuvant immunochemotherapy (nict) demonstrated significant advantages over neoadjuvant chemotherapy (nct) in patients with locally advanced gastric cancer. The nict group showed higher objective response rates (79.5% vs. 59.0%) and lower early recurrence rates (29.7% vs. 40.8%). While surgical complications were similar between both treatments, nict led to better pathological response rates and acted as an independent protective factor against early recurrence. Toxicity profiles were comparable, indicating nict’s safety and efficacy for this patient population.